FDA Fast Tracks ZW191 for Platinum-Resistant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted fast track designation to ZW191, an investigational antibody-drug conjugate developed by Zymeworks Inc., for patients with advanced or metastatic platinum-resistant ovarian cancer, with the goal of speeding development of a potential new treatment option for this difficult-to-treat disease.

Main data that support the findings of ZW191

ZW191 is designed to target folate receptor-α (FRα), a protein found in several types of tumors. According to the company, FRα is expressed in approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers and about 70% of lung adenocarcinomas. This makes it a relevant target for therapies aimed at treating patients with cancer.

The drug is an antibody-drug conjugate, meaning it combines a targeted antibody with a cancer-killing agent. ZW191 is engineered to bind to FRα-expressing cells and enter them. Once inside, it releases a payload known as ZD06519, a topoisomerase-1 inhibitor developed by Zymeworks. This payload is intended to kill tumor cells and may also affect nearby cancer cells through what is described as a bystander effect.

The FDA’s fast track designation is intended for treatments that address serious conditions and fill an unmet need. This designation may help speed up both the development and review process, potentially allowing patients to access new therapies sooner.

In a statement, the company noted that the designation was granted regardless of FRα expression. This suggests that ZW191 could potentially be used in a broader group of patients without requiring biomarker testing to confirm FRα levels before treatment.

Trial details

ZW191 is currently being studied in an ongoing phase 1 clinical trial. This early-stage study is enrolling patients with advanced solid tumors, including those with ovarian cancer, to better understand how the drug works in the body and how it affects tumors.

The trial is designed to evaluate several key factors. These include safety and tolerability, which look at how well patients handle the treatment, as well as pharmacokinetics, which examines how the drug is absorbed, distributed and processed in the body. Researchers are also assessing preliminary anti-tumor activity to see whether the drug shows signs of effectiveness in shrinking or controlling cancer.

The results from this study are expected to help guide future development of ZW191 and determine how it may be used in later-stage trials.

Safety

As ZW191 is still in early clinical testing, detailed safety results have not yet been reported. The ongoing phase 1 trial is specifically designed to evaluate side effects and determine the appropriate dose for future studies.

Researchers are monitoring patients closely to understand how the drug is tolerated and to identify any potential risks associated with treatment. This includes tracking both the type and severity of side effects that may occur during the study.

Further information on safety will become available as the trial progresses and more patients are treated. These data will be important in determining whether ZW191 can move forward in clinical development and potentially become a treatment option for patients with cancer.

Ovarian cancer background

Platinum-resistant ovarian cancer refers to disease that no longer responds to platinum-based chemotherapy, which is a common first-line treatment for patients with ovarian cancer. This type of cancer is considered more difficult to treat because it continues to grow or returns shortly after treatment with these therapies. Patients with advanced or metastatic disease may have cancer that has spread beyond the ovaries, further limiting treatment options and contributing to an ongoing unmet need for new therapies that can help control the disease and improve outcomes.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

References

1. “Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate” News Release, Globe Newswire. March 30^th, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.